

Please type a plus sign (+) inside this box →



Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 6

Complete if Known

Application Number 10/717,378
Filing Date November 19, 2003
First Named Inventor Rahman et al.
Group Art Unit 1654
Examiner Name Russel, Jeffrey
Attorney Docket Number 224491

U.S. PATENT DOCUMENTS

Examiner Initials	Doc. No.	U.S. Patent Document		Name of Patentee or Applicant	Date of Publication	Class / Subclass Filing Date if Appropriate
		Application or Patent Number	Kind Code			
RL	AF	3,993,754		Rahman et al.	Nov. 23, 1976	514/12
RL	AG	4,008,209		Fujino et al.	Feb. 15, 1977	530/313
RL	AH	4,016,100		Suzuki et al.	Apr. 5, 1977	264/43
RL	AI	4,115,544		Shell	Sep. 19, 1978	514/10
RL	AJ	4,224,179		Schneider	Sep. 23, 1980	264/4.6
RL	AK	4,229,360		Schneider et al.	Oct. 21, 1980	264/4.6
RL	AL	4,235,871		Papahadjopoulos et al.	Nov. 25, 1980	424/450
RL	AM	4,263,428		Apple et al.	Apr. 21, 1981	536/6.4
RL	AN	4,311,712		Evans et al.	Jan. 19, 1982	514/773
RL	AO	4,348,384		Horikoshi et al.	Sep. 7, 1982	424/450
RL	AP	4,370,349		Evans et al.	Jan. 25, 1983	424/365
RL	AQ	4,396,630		Riedl et al.	Aug. 2, 1983	424/365
RL	AR	4,411,894		Schrank et al.	Oct. 25, 1983	514/221
RL	AS	4,419,348		Rahman et al.	Dec. 6, 1983	514/34
RL	AT	4,473,692		Miyasaka et al.	Sep. 25, 1984	546/48
RL	AU	4,515,736		Deamer	May 7, 1985	424/1.21
RL	AV	4,522,803		Lenk et al.	June 11, 1985	424/1.21
RL	AW	4,545,880		Miyasaka et al.	Oct. 8, 1985	204/157.71
RL	AX	4,610,868		Fountain et al.	Sep. 9, 1986	424/1.1
RL	AY	4,721,612		Janoff et al.	Jan. 26, 1988	424/1.21
RL	AZ	4,812,312		Lopez-Berestein et al.	Mar. 14, 1989	424/417
RL	BA	4,857,319		Crowe et al.	Aug. 15, 1989	424/94.1
RL	BB	4,952,408		Rahman	Aug. 28, 1990	424/450
RL	BC	4,981,968		Wall et al.	Jan. 1, 1991	544/361
RL	BD	5,023,087		Yau-Young	June 11, 1991	424/450
RL	BE	5,077,057		Szoka, Jr.	Dec. 31, 1991	424/450
RL	BF	5,112,837	A	Burrows et al.	May 12, 1992	514/312
RL	BG	5,145,684	A	Liversidge et al.	Sep. 8, 1992	424/489
RL	BH	5,162,532	A	Comins et al.	Nov. 10, 1992	546/48
RL	BI	5,187,167	A	Hughes	Feb. 16, 1993	514/259
RL	BJ	5,247,089	A	Comins et al.	Sep. 21, 1993	546/48
RL	BK	5,352,789	A	Hinz	Oct. 4, 1994	546/48
RL	BL	5,389,377	A	Chagnon et al.	Feb. 14, 1995	424/450
RL	BM	5,391,745	A	Danishesky et al.	Feb. 21, 1995	546/48
RL	BN	5,415,867	A	Minchey et al.	May 16, 1995	424/450
RL	BO	5,422,344	A	Priel et al.	June 6, 1995	514/50
RL	BP	5,424,073	A	Rahman et al.	June 13, 1995	424/450
RL	BQ	5,447,936	A	Hausheer et al.	Sep. 5, 1995	514/283
RL	BR	5,468,859	A	Fortunak et al.	Nov. 21, 1995	546/48

Examiner Signature

Jeffrey E. Russel

Date Considered

January 5, 2005

* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Please type a plus sign (+) inside this box →



Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete if Known		
			Application Number	10/717,378	
			Filing Date	November 19, 2003	
			First Named Inventor	Rahman et al.	
			Group Art Unit	1654	
			Examiner Name	Russel, Jeffrey	
			Attorney Docket Number	224491	
Sheet	2	of	6		

BS	5,475,108	A	Comins et al.	Dec. 12, 1995	546/41
BT	5,496,830	A	Shapiro et al.	Mar. 5, 1996	514/283
BU	5,504,102	A	Agharkar et al.	Apr. 2, 1996	514/449
BV	5,527,913	A	Hinz	June 18, 1996	546/48
BW	5,541,327	A	Danishesky et al.	July 30, 1996	546/48
BX	5,552,154	A	Giovanella et al.	Sep. 3, 1996	424/449
BY	5,552,156	A	Burke	Sep. 3, 1996	424/450
BZ	5,560,923	A	Rahman et al.	Oct. 1, 1996	424/450
CA	5,608,066	A	Hinz	Mar. 4, 1997	546/48
CB	5,616,334	A	Janoff et al.	Apr. 1, 1997	424/404
CC	5,622,959	A	Priel et al.	Apr. 22, 1997	514/283
CD	5,648,090	A	Rahman et al.	July 15, 1997	424/450
CE	5,651,986	A	Brem et al.	July 29, 1997	424/484
CF	5,652,244	A	Giovanella et al.	Jul. 29, 1997	514/283
CG	5,665,710	A	Rahman et al.	Sep. 9, 1997	514/44
CH	5,674,873	A	Hausheer et al.	Oct. 7, 1997	514/283
CI	5,674,874	A	Hausheer et al.	Oct. 7, 1997	514/283
CJ	5,726,181	A	Hausheer et al.	Mar. 10, 1998	514/283
CK	5,736,156	A	Burke	Apr. 7, 1998	424/450
CL	5,759,767	A	Lakowicz et al.	June 2, 1998	435/4
CM	5,776,486	A	Castor et al.	July 7, 1998	424/450
CN	5,776,743	A	Frisch	July 7, 1998	435/6
CO	5,786,344	A	Ratain et al.	July 28, 1998	514/100
CP	5,837,282	A	Fenske et al.	Nov. 17, 1998	424/450
CQ	5,837,673	A	Tsujihara et al.	Nov. 17, 1998	514/2
CR	5,846,565	A	Brem et al.	Dec. 8, 1998	424/486
CS	5,859,022	A	Hausheer et al.	Jan. 12, 1999	514/283
CT	5,859,023	A	Hausheer et al.	Jan. 12, 1999	514/283
CU	5,880,133	A	Hausheer et al.	Mar. 9, 1999	514/283
CV	5,882,679	A	Needham	Mar. 16, 1999	424/450
CW	5,889,017	A	Giovanella et al.	Mar. 30, 1999	514/283
CX	5,900,419	A	Hausheer et al.	May 4, 1999	514/283
CY	5,916,596	A	Desai et al.	June 29, 1999	424/489
CZ	5,948,750	A	Garsky et al.	Sep. 7, 1999	514/2
DA	5,955,467	A	Hausheer et al.	Sep. 21, 1999	514/283
DB	5,958,937	A	Hausheer et al.	Sep. 28, 1999	514/283
DC	5,962,216	A	Trouet et al.	Oct. 5, 1999	435/4
DD	5,972,955	A	Duvvuri et al.	Oct. 26, 1999	514/283
DE	5,985,888	A	Wall et al.	Nov. 16, 1999	514/283
DF	5,998,426	A	Bedeschi et al.	Dec. 7, 1999	514/283
DG	6,015,901	A	Kawaguchi et al.	Jan. 18, 2000	546/89
DH	6,046,159	A	Hausheer et al.	Apr. 4, 2000	514/2

Examiner Signature	Jeffrey E. Russel	Date Considered	January 5, 2006
--------------------	-------------------	-----------------	-----------------

- * A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).
- * An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).



Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	10/717,378.
Filing Date	November 19, 2003
First Named Inventor	Rahman et al.
Group Art Unit	1654
Examiner Name	Russel, Jeffrey
Attorney Docket Number	224491

Sheet	3	of	6
-------	---	----	---

DI	6,056,973	A	Allen et al.	May 2, 2000	
DJ	6,057,361	A	Hausheer et al.	May 2, 2000	
DK	6,066,645	A	Hausheer et al.	May 23, 2000	
DL	6,069,134	A	Roth et al.	May 30, 2000	
DM	6,090,407	A	Knight et al.	July 18, 2000	
DN	6,096,336	A	Cao et al.	Aug. 1, 2000	
DO	6,146,659	A	Rahman	Nov. 14, 2000	
DP	6,291,676	B1	Burke et al.	Sep. 18, 2001	
DQ	6,355,268	B1	Slater et al.	Mar. 12, 2002	
DR	6,461,637	B1	Rahman	Oct. 8, 2002	
DS	6,548,071	B1	Cherian	Apr. 15, 2003	
DT	6,740,335	B1	Moynihan et al.	May 25, 2004	
DU	2002/0103141	A1	McKearn et al.	Aug. 1, 2002	
DV	2002/0119990	A1	Madden et al.	Aug. 28, 2002	
DW	2003/0059465	A1	Unger et al.	Mar. 27, 2003	
DX	2003/0215492	A1	Ahmad et al.	Nov. 20, 2003	
DY	2004/0009229	A1	Unger et al.	Jan. 15, 2004	
DZ	11/061,044		Ahmad et al.		Feb. 18, 2005
EA	60/247,306		Rahman et al.		Nov. 9, 2000
EB	60/294,285		Rahman et al.		May 29, 2001
EC	60/404,668		Rahman et al.		Aug. 20, 2002

FOREIGN PATENT DOCUMENTS

Examiner Initials	Doc. No.	Foreign Patent Document			Name of Patentee or Applicant	Date of Publication	Translation	
		Office	Application or Patent Number	Kind Code			Yes	No**
BN	ED	WO	83/03383	A1	The Liposome Co., Inc.	Oct. 13, 1983		
BN	EE	WO	86/01103	A1	The Liposome Co., Inc.	Feb. 27, 1986		
BN	EF	WO	93/18751	A1	Georgetown University	Sep. 30, 1993		
BN	EG	WO	95/08386	A1	Smithkline Beecham Corp.	April 6, 1995		
BN	EH	WO	96/11669	A1	Pharmacia, Inc.	April 25, 1996		
BN	EI	WO	98/17256	A1	Kirpotin	April 30, 1998		
BN	EJ	WO	99/13816	A2	Nexstar Pharmaceuticals, Inc.	March 25, 1999		
BN	EK	WO	99/51202	A2	Sequus Pharmaceuticals, Inc.	Oct. 14, 1999		
BN	EL	WO	00/23052	A1	ALZA Corp.	April 27, 2000		
BN	EM	WO	02/00168	A2	Supergen, Inc.	Jan. 3, 2002		
BN	EN	WO	02/058622	A2	Neopharm, Inc.	Aug. 1, 2003		
BN	EO	WO	03/030864	A1	Neopharm, Inc.	Apr. 17, 2003		
BN	EP	WO	03/103596	A2	Imarx Therapeutics, Inc.	Dec. 18, 2003		
BN	EQ	WO	04/017940	A3	Neopharm, Inc.	Mar. 4, 2004		
BN	ER	WO	04/035032	A2	Neopharm, Inc.	April 29, 2004		

OTHER - NON PATENT LITERATURE DOCUMENTS

Examiner	Doc	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item	Translation
----------	-----	---	-------------

Examiner Signature	Jeffrey E. Russell	Date Considered	January 5, 2006
--------------------	--------------------	-----------------	-----------------

* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Please type a plus sign (+) inside this box → +

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/717,378
				Filing Date	November 19, 2003
				First Named Inventor	Rahman et al.
				Group Art Unit	1654
				Examiner Name	Russel, Jeffrey
				Attorney Docket Number	224491
Sheet	4	of	6		

Initials	No.	(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Yes	No**
<i>ES</i>	ES	AKHTAR et al., <i>Journal of Controlled Release</i> , 22: 47-56 (1992)		
<i>ET</i>	ET	ALLEN et al., <i>Biochimica et Biophysica Acta</i> , 981(1): 27-35 (May 19, 1989)		
<i>EU</i>	EU	ALLEN et al., <i>Cancer Research</i> , 52: 2431-2439 (May 1, 1992)		
<i>EV</i>	EV	BLUME et al., <i>Biochimica et Biophysica Acta</i> , 1029(1): 91-97 (Nov. 2 1990)		
<i>EW</i>	EW	BURKE et al., <i>Journal of the American Chemical Society</i> , 114(21): 8318-8319 (Oct. 7, 1992)		
<i>EX</i>	EX	BURKE et al., <i>Biochemistry</i> , 32(20): 5352-5364 (May 25, 1993)		
<i>EY</i>	EY	BURRIS et al., <i>Journal of the National Cancer Institute</i> , 84(23), No. 23: 1816-1820 (Dec. 2, 1992)		
<i>EZ</i>	EZ	CAVALETTI et al., <i>Toxicology Letters</i> , 118: 103-107 (2000)		
<i>FA</i>	FA	Cecil Textbook of Medicine, 15 th Edition, Vol. 1: 396-399, 475-479 and 817-821 (1997)		
<i>FB</i>	FB	CHAKRABARTI et al., <i>Biochimica et Biophysica Acta</i> , 1108(2): 233-239 (1992)		
<i>FC</i>	FC	CLEMENTS et al., <i>Cancer Chemother Pharmacol</i> , 44: 411-416 (1999)		
<i>FD</i>	FD	CROMMELIN et al., <i>Pharmaceutical Research</i> , 4: 159-163 (July 1984)		
<i>FE</i>	FE	CROWE et al., <i>Archives of Biochemistry And Biophysics</i> , 220(2): 477-484 (Feb. 1983)		
<i>FF</i>	FF	CROWE et al., <i>Archives of Biochemistry And Biophysics</i> , 232(1): 400-407 (Jul. 1984)		
<i>FG</i>	FG	CROWE et al., <i>Biochimica et Biophysica</i> , 769: 151-159 (1984)		
<i>FH</i>	FH	CROWE et al., <i>Biochimica et Biophysica</i> , 769: 141-150 (1984)		
<i>FI</i>	FI	CROWE et al., <i>Archives Biochemistry And Biophysics</i> , 242(1): 240-247 (Oct. 1985)		
<i>FJ</i>	FJ	DAOUD et al., <i>Cancer Research</i> , 49: 2661-2667 (1989)		
<i>FK</i>	FK	DEAMER et al., <i>Liposomes</i> , (Ostro, eds), 27-51 (Marcel Dekker, Inc., New York, NY, 1983)		
<i>FL</i>	FL	DRUCKMANN et al., <i>Biochimica et Biophysica Acta</i> , 980(2): 381-384 (1989)		
<i>FM</i>	FM	EMERSON et al., <i>Cancer Research</i> , 55: 603-609 (1995)		
<i>FN</i>	FN	EMERSON et al., <i>Pharmaceutical Science & Technology Today</i> , 3(6): 205-209 (June 2000)		
<i>FO</i>	FO	ERICKSON-MILLER et al., <i>Cancer Chemother Pharmacol</i> , 39: 467-472 (1997)		
<i>FP</i>	FP	FAN et al., <i>Cancer Research</i> , 50: 3619-3626 (Jun. 15, 1990)		
<i>FQ</i>	FQ	FORSSEN et al., <i>Biochemical And Biophysical Research Communications</i> , 91(4): 1295-1301 (Dec. 28, 1979)		
<i>FR</i>	FR	FORSSEN et al., <i>Cancer Research</i> , 43: 546-550 (1983)		
<i>FS</i>	FS	FORSSEN et al., <i>Cancer Research</i> , 52: 3255-3261 (1992)		
<i>FT</i>	FT	FRY et al., <i>Analytical Biochemistry</i> , 90: 809-815 (1978)		
<i>FU</i>	FU	GABIZON et al., <i>Proc. Natl. Acad. Sci. USA</i> , 85: 6949-6953 (Sep. 1988)		
<i>FV</i>	FV	GABIZON et al., <i>Cancer Research</i> , 50: 6371-6378 (Oct. 1, 1990)		
<i>FW</i>	FW	GARCIA-CARBONERO et al., <i>Clinical Cancer Research</i> , 8: 641-661 (Mar. 2002)		
<i>FX</i>	FX	GIOVANELLA et al., <i>Science</i> , 246(4933): 1046-1048 (Nov. 24, 1989)		
<i>FY</i>	FY	GIOVANELLA et al., <i>Cancer Research</i> , 51: 3052-3055 (Jun. 1, 1991)		
<i>FZ</i>	FZ	GOKHALE et al., <i>British Journal of Cancer</i> , 74: 43-48 (1996)		
<i>GA</i>	GA	GREEN CROSS CORPORATION, <i>Chemical Abstracts</i> , 97:11851g: (1982)		
<i>GB</i>	GB	GREGORIADIS et al., <i>The New England Journal of Medicine</i> , 295(12): 704-710 (1976)		

Examiner Signature	<i>Jeffrey E. Russel</i>	Date Considered	<i>January 5, 2006</i>
--------------------	--------------------------	-----------------	------------------------

- * A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).
- + An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Please type a plus sign (+) inside this box →



Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/717,378
				Filing Date	November 19, 2003
				First Named Inventor	Rahman et al.
				Group Art Unit	1654
				Examiner Name	Russel, Jeffrey
				Attorney Docket Number	224491
Sheet	5	of	6		

GC	GROCHOW et al., <i>Drug Metabolism and Disposition</i> , 20(5): 706-713 (1992)		
GD	GUICHARD et al., <i>Clinical Cancer Research</i> , 4: 3089-3094 (Dec. 1998)		
GE	HARDMAN et al., <i>Anticancer Research</i> , 19: 2269-2274 (1999)		
GF	HARDMAN et al., <i>British Journal of Cancer</i> , 81(3): 440-8 (Oct. 1999)		
GG	HILLERY, <i>Advanced Drug Delivery Reviews</i> , 24(2 & 3): 345-363 (1997)		
GH	HONG et al., <i>J. Med. Chem.</i> , Computer Search Listing Abstract (May 1990)		
GI	HONG et al., <i>Cancer Research</i> , Computer Search Listing Abstract (Jul. 15, 1990)		
GJ	HSIANG et al., <i>Cancer Research</i> , 48: 1722-1726 (Apr. 1, 1988)		
GK	HUANG et al., <i>Cancer Research</i> , 52: 5135-5143 (Oct. 1, 1992)		
GL	INNOCENTI et al., <i>Drug Metabolism & Dispositions</i> , 29(4): 596-600 (2001)		
GM	JANOFF et al., <i>Journal of Liposome Research</i> , 3(3): 451-471 (1993)		
GN	JANSEN et al., <i>International Journal of Cancer</i> , 70(3): 335-340 (Jan. 27, 1997)		
GO	JETT et al., <i>Methods in Enzymology</i> , 141: 459-466 (1983)		
GP	KAWATO et al., <i>Cancer Research</i> , 51(16): 4187-91 (Aug. 15, 1991)		
GQ	KAWATO et al., <i>Cancer Chemotherapy and Pharmacology</i> , 28(3): 192-198 (1991)		
GR	KILLION et al., <i>Journal of the National Cancer Institute</i> , 81(18): 1387-1392 (Sep. 6, 1989)		
GS	KNOTTING et al., <i>Cancer-Chemother-Pharmacol.</i> , Computer Search Listing Abstract (1992)		
GT	LASIC, <i>American Scientist</i> , 80(1): 20-31 (Jan.-Feb. 1992)		
GU	LASIC, <i>Nature</i> , 355(6357): 272-280 (Jan. 16, 1992)		
GV	LAVELLE et al., <i>Seminars in Oncology</i> 23(1) Suppl.3: 11-20 (Feb. 1996)		
GW	LUNDBERG, <i>Anti-Cancer Drug Design</i> , 13: 453-461 (1998)		
GX	MACHIDA et al., <i>Journal of Controlled Release</i> , 66: 159-175 (2000)		
GY	MACHY et al., <i>Biochimica et Biophysica Acta</i> , 730: 313-320 (1983)		
GZ	MADDEN et al., <i>Biochimica et Biophysica Acta</i> , 817: 67-74 (1985)		
HA	MADDEN et al., <i>Chemistry and Physics of Lipids</i> , 53: 37-46 (1990)		
HB	MADDEN et al., <i>Proc. Of ASCO</i> , 17: abstract #754: (1998)		
HC	MARGALIT et al., <i>Journal of Controlled Release</i> , 17(3): 285-296 (1991)		
HD	MATHIJSEN et al., <i>Clinical Cancer Research</i> , 7: 2182-2194 (Aug. 2001)		
HE	MAYER et al., <i>Cancer Research</i> , 49: 5922-5930 (1989)		
HF	MAYER et al., <i>Biochimica et Biophysica Acta</i> , 1025: 143-151 (1990)		
HG	MCCABE et al., <i>Cancer Investigation</i> , 12(3): 308-313 (1994)		
HH	MONKS et al., <i>Journal of the National Cancer Institute</i> , 83(11): 757-766 (Jun. 5, 1991)		
HI	OKUNO et al., <i>Cancer Research</i> , 60: 2988-2995 (Jun. 1, 2000)		
HJ	O'LEARY et al., <i>Clinical Cancer Research</i> , 5: 181-187 (Jan. 1999)		
HK	OLITZKI, <i>In vivo Procedures, Bibliotheca Microbiologica</i> , 9: 196-203 (1970)		
HL	ORMROD et al., <i>ADIS Drug Evaluation</i> , 58(3): 534-551 (1999)		
HM	PAGANO, <i>Annual Review of Biophysics and Bioengineering</i> , 7: 435-468 (1978)		
HN	PALMISANO et al., <i>Anal-Chem.</i> , Computer Listing Search Abstract, (May 1, 1989)		
HO	PANTAZIS et al., <i>Cancer Research</i> , 52: 3980-3987 (Jul. 15, 1992)		

Examiner Signature	Jeffrey E. Russel	Date Considered	January 5, 2006
--------------------	-------------------	-----------------	-----------------

- * A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).
- * An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Please type a plus sign (+) inside this box →



Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	10/717,378
Filing Date	November 19, 2003
First Named Inventor	Rahman et al.
Group Art Unit	1654
Examiner Name	Russel, Jeffrey
Attorney Docket Number	224491

Sheet 6 of 6

HP	PAPAHADJOPOULOS et al., <i>Proc. Natl. Acad. Sci. USA</i> , 88: 11460-11464 (Dec. 1991)		
HQ	PARTEARROYO et al., <i>FEBS Letters</i> , 302(2): 138-140 (May 1992)		
HR	PEJAVER et al., <i>Drug Development and Industrial Pharmacy</i> , 13(15): 2633-2649 (1987)		
HS	PEREZ-SOLER, <i>Cancer Treatment Reviews</i> , 16(2): 67-82 (Jun. 1989)		
HT	PEREZ-SOLER et al., <i>Cancer Research</i> , 50: 4254-4259 (Jul. 15, 1990)		
HU	PINNADUWAGE et al., <i>Biochemistry</i> , 31(11): 2850-2855 (Mar. 24, 1992)		
HV	PIZZOLATO et al., <i>Lancet</i> , 361: 2235-2242 (Jun. 28, 2003)		
HW	POTMESIL et al., <i>DNA Topoisomerases Cancer</i> , <i>Chemical Abstract</i> 117(103,369): (1991)		
HX	RACKER, <i>J. Membrane Biol.</i> , 10: 221-235 (1972)		
HY	RAHMAN et al., <i>Cancer Research</i> , 45: 796-803 (Feb. 1985)		
HZ	RAHMAN et al., <i>J. of the Nat. Cancer Institute</i> , 81(23): 1794-1800 (Dec. 6, 1989)		
IA	RATAIN et al., <i>Journal of Clinical Oncology</i> , 20(1): 7-8 (Jan. 1, 2002)		
IB	RIEGER, <i>Pharmaceutical Dosage Forms Disperse System</i> , 1(8): 334-338 (1988)		
IC	SENIOR et al., <i>Biochimica et Biophysica Acta</i> , 1070: 173-179 (1991)		
ID	SHELLY et al., <i>Proc. Natl. Acad. Sci. USA</i> , 89: 9039-9043, (Oct. 1992)		
IE	SHULKIN et al., <i>J. Microencapsulation</i> , 1(1): 73-80 (1984)		
IF	STORM et al., <i>Cancer Research</i> , 47: 3366-3372 (Jul. 1, 1987)		
IG	SUGARMAN et al., <i>1-Pharmacology</i> , <i>Chemical Abstract No.</i> 124:332078g, 124(25): 94 (1996)		
IH	SUPERSAXO et al., <i>Pharmaceutical Research</i> , 8(10): 1286-1291 (Oct. 1991)		
II	SZOKA et al., <i>Proc. Natl. Acad. Sci. USA</i> , 75(9): 4194-4198 (Sep. 1978)		
IJ	SZOKA, <i>Ann. Rev. Biophys. Bioeng.</i> , 9: 467-508 (1980)		
IK	TARDI et al., <i>Cancer Research</i> , 60: 3389-3393 (Jul 1, 2000)		
IL	THIES et al., <i>Analytical Biochemistry</i> , 188: 65-71 (1990)		
IM	THOMPSON et al., <i>Biochimica et Biophysica Acta</i> , 1400: 301-319 (1998)		
IN	TOPCHIEVA et al., <i>Biomed-Sci.</i> , Computer Listing Search Abstract, (1991)		
IO	TSYGANENKO et al., <i>Antibiotiki</i> , 28(8): 577-581 (1983)		X*
IP	USOV et al., <i>Bioorg-Khim.</i> , Computer Listing Search Abstracts, (1991)		
IQ	VION-DURY et al., <i>J. Pharm. And Exp. Therapeutics</i> , 250(3): 1113-1119 (1989)		
IR	WADKINS et al., <i>Cancer Research</i> , 59(14): 3424-8 (Jul 15, 1999)		
IS	WALL et al., <i>J. of the American Chem. Soc.</i> , 88(16): 3888-3890 (1966)		
IT	WEINSTEIN, <i>Liposomes</i> , (Ostro eds), 277-338 (Marcel Dekker, Inc., New York, NY, 1983)		
IU	WILLIAMS et al., <i>J. Controlled Release</i> , 91: 167-172 (2003)		
IV	WOODLE et al., <i>Methods in Enzymology</i> , 171: 193-217 (1989)		
IW	WU et al., <i>Chemical Abstracts</i> , 99:163963z: (1983)		
IX	YOKOYAMA et al., <i>Cancer-Res.</i> , Computer Listing Search Abstract, (1991)		

Examiner Signature

Jeffrey E. Russel

Date Considered

January 5, 2006

* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).